Skip to main content

SYSTEMATIC REVIEW article

Front. Tuberc
Sec. Epidemiology of Tuberculosis
Volume 2 - 2024 | doi: 10.3389/ftubr.2024.1393972

Pooled Prevalence of Bacteriologically Confirmed Rifampicin-Resistant Mycobacterium tuberculosis among children in Ethiopia: A systematic review and meta-analysis

Provisionally accepted
Tilahun Beyene Handiso Tilahun Beyene Handiso 1*Abera B. Mekiso Abera B. Mekiso 2Markos S. Jifar Markos S. Jifar 2Shemsu Nuriye Shemsu Nuriye 3Tafesework W. Alula Tafesework W. Alula 4
  • 1 Wachemo University, Hosaena, Ethiopia
  • 2 Department of Public Health, College of Medicine and Health Sciences, Wachemo University, Hossana, Ethiopia
  • 3 School of Public Health, College of Health Sciences and Medicine, Wolaita Sodo University, Sodo, Southern Nations, Nationalities, and Peoples' Region, Ethiopia
  • 4 Hossana College of Health Science, Hossan, Ethiopia

The final, formatted version of the article will be published soon.

    Background: Drug-resistant tuberculosis represents a major threat to the fight against TB around the world. Multi-drug-resistant tuberculosis (MDR-TB) is tuberculosis caused by strains of Mycobacterium tuberculosis resistant to at least isoniazid and rifampicin. In Ethiopia, screening bacteriologically confirmed drug resistant TB among children would be impractical to get precise and valid prevalence estimates. Therefore, the valid burden of tuberculosis (TB) among children and adolescents is not well known. Thus, this review aimed to pool the prevalence of bacteriologically Confirmed Rifampicin-Resistant Mycobacterium tuberculosis among children in Ethiopia.This systematic review and meta-analysis was conducted according to the Joanna Briggs Institute (JBI) systematic review of performance evidence method and reported per the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2017 guideline.We searched the published primary studies from electronic databases: PubMed, EMBASE, Scopus, Web of Science, and Google Scholar using free text and MeSH terms for studies published in English since 2015. We analyzed the data using STATA version 14. We carried out a metaanalysis to estimate the pooled prevalence of multi-drug-resistant TB among TB cases and presumptive children under 18 years old with their 95% confidence interval (CI) using a random effect model.We retrieved a total of 45 articles. Finally, six records met the eligibility criteria and were included in the meta-analysis. The pooled prevalence of Rifampicin-Resistant TB among TB-presumptive children in Ethiopia was 1% (95% CI: 0%, 1.0%), I 2 = 0.0%, p <0.001. The pooled prevalence of Rifampicin-Resistant TB among children with TB taking first-line anti-TB drugs in Ethiopia was 8% (95% CI: 5%, 11%), I 2 = 0%, p<0.001.Rifampicin-resistant TB is more prevalent among children with TB who were on first-line anti-TB drugs compared to TB presumptive children in Ethiopia. Therefore, strengthening prevention and control is crucial in order to reduce the impact of drug resistant TB and drug susceptible TB.

    Keywords: Multi-drug, resistant, Tuberculosis, Children, Ethiopia

    Received: 29 Feb 2024; Accepted: 22 Jul 2024.

    Copyright: © 2024 Handiso, Mekiso, Jifar, Nuriye and Alula. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Tilahun Beyene Handiso, Wachemo University, Hosaena, Ethiopia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.